เอกสารอ้างอิง

[1] Zigrino P, Steiger J, Fox JW, Loffek S, Schild A, Nischt R, et al. Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration. J Biol Chem. 2007; 282(42): 30785-93.

[2] Mauch C, Zamek J, Abety AN, Grimberg G, Fox JW, Zigrino P. Accelerated wound repair in ADAM-9 knockout animals. J Invest Dermatol. 2010; 130(8): 2120-30.

[3] Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their hibitors in oral lichen planus.J Cutan Pathol. 2001; 28(2): 72-82.

[4] Mazzarella N, Femiano F, Gombos F, De Rosa A, Giuliano M. Matrix metalloproteinase gene expression in oral lichen planus: erosive vs. reticular forms. J Eur Acad Dermatol Venereol. 2006; 20(8): 953-7.

[5] Chen Y, Zhang W, Geng N, Tian K, Jack Windsor L. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus. Head Neck. 2008;30(9):1237-45.

[6] Paulusova V, Laco J, Drizhal I, Slezak R. Expression of matrix metalloproteinase 9 in patients with oral lichen planus. ActaMedica (Hradec Kralove). 2012;55(1):23-6.

[7] Ertugrul AS, Dursun R, Dundar N, Avunduk MC, Hakki SS. MMP-1, MMP-9, and TIMP-1 levels in oral lichen planus patients with gingivitis or periodontitis. Arch Oral Biol. 2013; 58(7): 843-52.

[8] da Silva Fonseca LM, do Carmo MA. Identification of the AgNORs, PCNA and ck16 proteins in oral lichen planus lesions. Oral Dis. 2001; 7(6): 344-8.

[9] Mega H, Jiang WW, Takagi M. Immunohistochemical study of oral lichen planus associated with hepatitis C virus infection, oral lichenoid contact sensitivity reaction and idiopathic oral lichen planus. Oral Dis. 2001; 7(5): 296-305.

[10] Lee JJ, Kuo MY, Cheng SJ, Chiang CP, Jeng JH, Chang HH, et al. Higher expressions of p53 and proliferating cell nuclear antigen (PCNA) in atrophic oral lichen plan us and patients with areca quid chewing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 99(4): 471-8.

[11] Sousa FA, Paradella TC, Carvalho YR, Rosa LE. Immunohistochemical expression of PCNA, p53, bax and bcl-2 in oral lichen plan us and epithelial dysplasia. J Oral Sci. 2009; 51(1): 117-21.

[12] Pramod R, Pandit S, Desai D, Suresh K, Ingaleshwar P, Shetty S, et al Immunohistochemical assessment of proliferating cell nuclear antigen protein expression in plaque, reticular and erosive types of oral lichenplanus. Ann Med Health Sci Res. 2014; 4(4): 598-602.

[13] Scully C, Beyli M, Ferreiro MC, Ficarra G, Gill Y, Griffiths M, et al. Update on oral lichen planus: etiopathogenesis and management. Crit Rev Oral Biol Med. 1998; 9(1): 86-122.

[14] Sugerman PB, Savage NW, Walsh LJ, Zhao ZZ, Zhou XJ, Khan A, et al. The pathogenesis of oral lichen planus.Crit Rev Oral Biol Med. 2002; 13(4): 350-65.

[15] Dissemond J. Oral lichen planus: an overview. J Dermatolog Treat. 2004; 15(3): 136-40.

[16] Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: tiopathogenesis, diagnosis, management and malignant transformation. J Oral Sci. 2007; 49(2): 89-106.

[17] Roopashree MR, Gondhalekar RV, Shashikanth MC, George J, Thippeswamy SH, Shukla A. Pathogenesis of oral lichen planus--a review. J Oral Pathol Med. 2010; 39(10): 729-34.

[18] Lavanya N, Jayanthi P, Rao UK, Ranganathan K. Oral lichen planus: An update on pathogenesis and treatment. J Oral MaxillofacPathol. 2011; 15(2): 127-32.

[19] McCartan BE, Healy CM. The reported prevalence of oral lichen planus: a review and critique. J Oral Pathol Med. 2008; 37(8): 447-53.

[20] Thongprasom K, Youngnak-Piboonratanakit P, Pongsiriwet S, Laothumthut T, Kanjanabud P, Rutchakitprakarn L. A multicenter study of oral lichen planus in Thai patients. J Investig Clin Dent. 2010; 1(1): 29-36.

[21] วิไลรัตน์ สฤษฎีชัยกุล. ไลเคน แพลนัส. ใน: เวชศาสตร์ช่องปากขั้นสูง (Advanced oral medicine). กอบกาญจน์ ทองประสม, บรรณาธิการ. พิมพ์ครั้งที่ 2. กรุงเทพฯ : สำนักพิมพ์แห่งจุฬาลงกรณ์มหาวิทยาลัย; 2553. หน้า 85-114, ISBN 978-972-03-2530-7.

[22] Carrozzo M, Thorpe R. Oral lichen planus: a review. Minerva Stomatol. 2009; 58(10): 519-37.

[23] Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen plan us: clinical features and management. Oral Dis. 2005; 11(6): 338-49.

[24] Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005; 100(1): 40-51.

[25] Rogers RS, 3rd, Eisen D. Erosive oral lichen planus with genital lesions: the vulvovaginal-gingival syndrome and the peno-gingival syndrome. Dermatol Clin. 2003; 21(1): 91-8, vi-vii.

[26] Al-Hashimi I, Schifter M, Lockhart PB, Wray D, Brennan M, Migliorati CA, et al. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 103 Suppl: S25.e1-12.

[27] Mravak-Stipetic M, Loncar-Brzak B, Bakale-Hodak I, Sabol I. Clinicopathologic correlation of oral lichen planus and oral lichenoid lesions: a preliminary study. 2014; 2014: 746874.

[28] Neville BW, Damm DD, Allen CM, Bouquot J. Oral & maxillofacial pathology. 3rd ed., Philadelphia, Saunders, 2009, pp 782-789, ISBN 978-1-4160-3435-3.

[29] Regezi JA, Sciubba JJ, Jordan RCK. Oral pathology: clinical pathologic correlations. 6th ed., St. Louis, Saunders; 2012, pp. 97-102, ISBN 978-1-4557-0262-6

[30] Iraji F, Asilian A, Saeidi A, Siadat AH, Saeidi AR, Hassanzadeh A. Comparison of the rapeutic effect of low-dose low-molecular-weight heparin (enoxaparin) vs. oral prednisone in treatment of patients with lichen planus; A clinical trial. Adv Biomed Res. 2013; 2: 76.

[31] Georgakopoulou EA, Andreadis D, Arvanitidis E, Loumou P. Biologic agents and oral diseases -- an update on clinical applications. Acta Dermatovenerol Croat. 2013; 21(1): 24-34.

[32] Koray M, Dulger O, Ak G, Horasanli S, Ucok A, Tanyeri H, et al. The evaluation of anxiety and salivary cortisol levels in patients with oral lichen planus. Oral Dis. 2003; 9(6): 298-301.

[33] Girardi C, Luz C, Cherubini K, de Figueiredo MA, Nunes ML, Salum FG. Salivary cortisol and dehydroepiandrosterone (DHEA) levels, psychological factors in patients with oral lichen planus. Arch Oral Biol. 2011; 56(9): 864-8.

[34] Nadendla LK, Meduri V, Paramkusam G, Pachava KR. Association of salivary cortisol and anxiety levels in lichen planus patients. J Clin Diagn Res. 2014; 8(12): Zc01-3.

[35] Sandhu SV, Sandhu JS, Bansal H, Dua V. Oral lichen planus and stress: An appraisal. Contemp Clin Dent. 2014; 5(3): 352-6.

[36] Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 2007; 36(10): 575-80.

[37] Georgakopoulou EA, Achtari MD, Achtaris M, Foukas PG, Kotsinas A. Oral lichen plan us as a preneoplastic inflammatory model.J Biomed Biotechnol. 2012; 2012: 759626.

[38] van der Waal I. Potentially malignant disorders of the oral and oropharyngeal mucosa; terminology, classification and present concepts of management. Oral Oncol. 2009; 45(4-5): 317-23.

[39] Bombeccari GP, Guzzi G, Tettamanti M, Gianni AB, Baj A, Pallotti F, et al. Oral lichen planus and malignant transformation: a longitudinal cohort study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011; 112(3): 328-34.

[40] Mattila R, Rautava J, Syrjanen S. Human papillomavirus in oral atrophic lichen planus lesions. OralOncol. 2012; 48(10): 980-4.

[41] Reiss K, Saftig P. The 'A DisintegrinAnd Metalloprotease' (ADAM) family of sheddases: Physiological and cellular functions. Seminars in Cell and Developmental Biology. 2009(2): 126.

[42] Mahimkar RM, Visaya O, Pollock AS, Lovett DH. The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J. 2005; 385(Pt 2): 461-8.

[43] Dijkstra A, Postma DS, Noordhoek JA, Lodewijk ME, Kauffman HF, ten Hacken NH, et al. Expression of ADAMs ("a disintegrin and metalloprotease") in the human lung. Virchows Arch. 2009; 454(4): 441-9.

[44] Weskamp G, Kratzschmar J, Reid MS, Blobel CP. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J Cell Biol. 1996; 132(4): 717- 26.

[45] White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003; 15(5): 598-606.

[46] Horiuchi K, Zhou HM, Kelly K, Manova K, Blobel CP. Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins beta1 and beta2. Dev Biol. 2005; 283(2): 459-71.

[47] Diegelmann RF, Evans MC. Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci. 2004; 9: 283-9.

[48] Kawaguchi M, Hearing VJ. The Roles of ADAMs Family Proteinases in Skin Diseases. Enzyme Res. 2011; 2011: 482498.

[49] Franzke CW, Bruckner-Tuderman L, Blobel CP. Shedding of collagen XVII/BP180 in skin depends on both ADAM10 and ADAM9. J Biol Chem. 2009;284(35):23386-96.

[50] Franzke CW, Tasanen K, Schacke H, Zhou Z, Tryggvason K, Mauch C, et al. Transmembrane collagen XVII, an epithelial adhesion protein, is shed from the cell surface by ADAMs. Embo j. 2002; 21(19): 5026-35.

[51] Peduto L. ADAM9 as a potential target molecule in cancer. Curr Pharm Des. 2009; 15(20): 2282-7.

[52] Peduto L, Reuter VE, Shaffer DR, Scher HI, Blobel CP. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 2005; 65(20): 9312-9.

[53] Guaiquil V, Swendeman S, Yoshida T, Chavala S, Campochiaro PA, Blobel CP. ADAM9 is involved in pathological retinal neovascularization. Mol Cell Biol. 2009; 29(10): 2694-703.

[54] Mazzocca A, Coppari R, De Franco R, Cho JY, Libermann TA, Pinzani M, et al. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. Cancer Res. 2005; 65(11): 4728-38.

[55] Hirao T, Nanba D, Tanaka M, Ishiguro H, Kinugasa Y, Doki Y, et al. Overexpression of ADAM9 enhances growth factor-mediated recycling of E-cadherin in human colon cancer cell line HT29 cells. Exp Cell Res. 2006; 312(3): 331-9.

[56] Ambatipudi S, Gerstung M, Gowda R, Pai P, Borges AM, Schaffer AA, et al. Genomic profiling of advanced-stage oral cancers reveals chromosome 11q alterations as markers of poor clinical outcome. PLoS One. 2011; 6(2): e17250.

[57] Vincent-Chong VK, Anwar A, Karen-Ng LP, Cheong SC, Yang YH, Pradeep PJ, et al. Genome wide analysis of chromosomal alterations in oral squamous cell carcinomas revealed over expression of MGAM and ADAM9. PLoS One. 2013; 8(2): e54705.

[58] Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol. 1978; 121(6): 2228-34.

[59] Mathews MB, Bernstein RM, Franza BR, Garrels JI. Identity of the proliferating cell nuclear antigen and cyclin.Nature. 1984; 309(5966): 374-6.

[60] Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci. 2003; 116(Pt 15): 3051-60.

[61] Kelman Z. PCNA: structure, functions and interactions. Oncogene. 1997; 14(6): 629-40.

[62] Saghafi S, Zare-Mahmoodabadi R, Salehinejad J, Kadeh H, Afzal-Aghaee M. Immunohistochemical analysis of p53 and PCNA expression in calcifying odontogenic cyst. J Oral Sci. 2010;52(4):609-13.

[63] Seyedmajidi M, Nafarzadeh S, Siadati S, Shafaee S, Bijani A, Keshmiri N. p53 and PCNA Expression in Keratocystic Odontogenic Tumors Compared with Selected Odontogenic Cysts. Int J Mol Cell Med. 2013; 2(4): 185-93.

[64] de Sousa FA, Paradella TC, Carvalho YR, Rosa LE. Comparative analysis of the expression of proliferating cell nuclear antigen, p53, bax, and bcl-2 in oral lichen plan us and oral squamous cell carcinoma. Ann DiagnPathol. 2009; 13(5): 308-12.

[65] Thongprasom K, Luangjarmekorn L, Sererat T, Taweesap W. Relative efficacy of fluocinoloneacetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992; 21(10): 456-8.

[66] Wewers ME, Lowe NK. A critical review of visual analogue scales in the measurement of clinical phenomena. Res Nurs Health. 1990; 13(4): 227-36.

[67] Iamaroon A, Krisanaprakornkit S. Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol. 2009;45(10):e175-9.

[68] Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect Immun. 1998; 66(9): 4222-8.

[69] Krisanaprakornkit S, Chotjumlong P, Kongtawelert P, Reutrakul V. Involvement of phospholipase D in regulating expression of anti-microbial peptide human beta-defensin-2. IntImmunol. 2008; 20(1): 21-9.

[70] Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomainproteins with multiple functions. Genes Dev. 2003; 17(1): 7-30.

[71] Lopez-Jornet P, Camacho-Alonso F. Quality of life in patients with oral lichen planus. J EvalClinPract. 2010; 16(1): 111-3.

[72] Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen plan us. Cochrane Database Syst Rev. 2011(7): Cd001168.

[73] Baccaglini L, Thongprasom K, Carrozzo M, Bigby M. Urban legends series: lichen plan us. Oral Dis. 2013; 19(2): 128-43.